Pitt-Hopkins Syndrome

1. Disease Information

Overview

Pitt-Hopkins syndrome (PTHS) is a rare neurodevelopmental disorder first described by Pitt and Hopkins in 1978 in two unrelated patients (chen2021molecularandcellular pages 1-2). PTHS is characterized by the association of intellectual deficit, characteristic facial dysmorphism, and abnormal/irregular breathing (sweetser2025pitthopkinssyndrome pages 1-1). It is classified as a syndromic form of autism spectrum disorder (ASD) caused by autosomal dominant mutations in the transcription factor 4 (TCF4) gene (chen2021molecularandcellular pages 1-2, martinowich2023evaluationofnav1.8 pages 1-2).

Key Identifiers

Table: This table summarizes the core identifiers and defining characteristics of Pitt-Hopkins syndrome, including disease and gene IDs, inheritance, locus, and prevalence. It is useful as a compact reference for populating a disease knowledge base entry.

Synonyms and Alternative Names

Common synonyms include: PTHS; Pitt-Hopkins mental retardation syndrome; syndromal mental retardation with intermittent hyperventilation; TCF4-related disorder. TCF4 is also known as ITF2, E2-2, FECD3, and SEF2 (chen2021molecularandcellular pages 1-2, chiu2024skeletalmusclevulnerability pages 1-2).

2. Etiology

Disease Causal Factors

PTHS is a monogenic disorder caused by functional haploinsufficiency of the TCF4 gene (OMIM *602272), located at chromosomal region 18q21.2 (zhao2024clinicalandgenetic pages 1-2, jiang2024agenotypicand pages 1-2). TCF4 encodes a type I basic helix-loop-helix (bHLH) transcription factor that dimerizes with itself or other E-protein family members. The TCF4 dimer complex recognizes E-box (CANNTG) sequences within promoter and enhancer regions of target genes, regulating their expression (chen2021molecularandcellular pages 1-2).

Genetic Risk Factors

A variety of causal mutations within the TCF4 locus have been identified, including missense, nonsense, frameshift, and splice-site point mutations, as well as small and large deletions. Over 140 different TCF4 mutations have been documented (jiang2024agenotypicand pages 1-2). Depending on the mutation, the affected allele leads to haploinsufficient expression of TCF4 protein or expression of a truncated/mutated protein capable of acting in a dominant-negative or hypomorphic manner (chen2021molecularandcellular pages 1-2). The majority of de novo mutations lie within the evolutionarily conserved bHLH domain required for dimerization and DNA binding (chen2021molecularandcellular pages 1-2). Mutations in the 5' end of the gene affecting only long isoforms are associated with mild to moderate nonsyndromic intellectual disability without typical PTHS features (chen2021molecularandcellular pages 1-2, popp2022therecurrenttcf4 pages 2-3). In a 47-patient cohort, approximately 13% involved copy number variants and 23% had pathogenic missense variants, with 19 novel variants identified (zhao2024clinicalandgenetic pages 3-5). Mutations in exons 7 and 8 correlate with severe intellectual disability and typical PTHS features, while variants in exons 1–6 present milder phenotypes (zhao2024clinicalandgenetic pages 7-9, popp2022therecurrenttcf4 pages 2-3).

Environmental and Protective Factors

As a monogenic disorder caused by de novo mutations, PTHS does not have established environmental risk factors, protective factors, or gene-environment interactions. The disease is entirely genetic in origin.

3. Phenotypes

The following table summarizes the major clinical phenotypes observed in PTHS with their frequencies and suggested HPO terms.

Table: This table summarizes the major reported clinical features of Pitt-Hopkins syndrome, including approximate frequencies, suggested HPO mappings, and broad phenotype categories. It is useful for phenotype curation and disease knowledge base population.

Detailed Phenotype Characteristics

Craniofacial features are hallmark findings and include square forehead, full cheeks/prominent midface, wide mouth with full lips, thickened/overfolded helix, short neck, and slender fingers, all reported at 100% frequency in a 47-patient cohort (zhao2024clinicalandgenetic pages 3-5). Additional facial features include deep-set eyes, furrowing in the frontonasal region, beaked nose with downturned nasal tip, protruding lower face, and Cupid's bow-shaped upper lip (popp2022therecurrenttcf4 pages 2-3). However, not all patients present with typical facial features, complicating clinical diagnosis (jiang2024agenotypicand pages 1-2).

Neurological features include severe global developmental delay (95%), absent or very limited speech (91%), muscular hypotonia (93%), gait ataxia (93%), and brain MRI abnormalities (79%) including ventricle enlargement (45%), wide extracranial space (34%), and corpus callosum hypoplasia (13%) (zhao2024clinicalandgenetic pages 3-5). Seizure activity is reported in approximately 11% of a recent Chinese cohort, though historical reports suggest 30–50% prevalence (zhao2024clinicalandgenetic pages 2-3, chen2021molecularandcellular pages 1-2). Motor or speech regression occurs in approximately 6% of cases (zhao2024clinicalandgenetic pages 3-5).

Breathing abnormalities involve episodes of hyperventilation followed by apnea during wakefulness, affecting over 50% of PTHS patients (cleary2021disorderedbreathingin pages 1-2, cleary2021disorderedbreathingin pages 2-3). These include periodic breathing characterized by repeated cycles of waxing and waning minute ventilation, reduced sigh activity, and prolonged post-sigh apnea (cleary2021disorderedbreathingin pages 1-2, cleary2021disorderedbreathingin pages 9-9).

Behavioral features include a characteristically happy/smiling appearance (91%), autism spectrum disorder meeting diagnostic criteria in 67% of assessed patients, anxiety/agitation (48%), and stereotypic hand movements (100%) (zhao2024clinicalandgenetic pages 3-5, zhao2024clinicalandgenetic pages 2-3).

Gastrointestinal involvement includes constipation (66%) and food intolerances/allergies (81%) (zhao2024clinicalandgenetic pages 2-3).

Ophthalmological features include visual anomalies (85%) such as myopia, strabismus, and astigmatism (zhao2024clinicalandgenetic pages 3-5).

Musculoskeletal involvement includes skeletal muscle vulnerability, with a recent study demonstrating myopathological changes including fiber type I predominance, complement cascade activation, and mitochondrial vulnerability in muscle biopsy from a PTHS patient (chiu2024skeletalmusclevulnerability pages 1-2).

Age of Onset and Progression

Typical onset occurs in infancy, with diagnosis established when infants fail to reach developmental milestones (dennys2024mecp2genetherapy pages 1-2, james2025juvenilereinstatementof pages 1-5). Delayed motor milestones include delayed sitting (78%) and delayed walking (93%). Only 16% develop any speech by a mean age of 2.6 years (zhao2024clinicalandgenetic pages 2-3). The condition is chronic and lifelong, with non-progressive features after the initial developmental period.

4. Genetic/Molecular Information

Causal Gene

TCF4 (transcription factor 4, HGNC:11634, NCBI Gene ID: 6925, Ensembl: ENSG00000196628) on chromosome 18q21.2 is the sole established causal gene (OpenTargets Search: Pitt-Hopkins syndrome, zhao2024clinicalandgenetic pages 1-2). The human TCF4 gene spans 437 kb and contains 41 exons, producing 18 unique protein isoforms with differing N-terminals and conserved C-terminals (chen2021molecularandcellular pages 2-3). Functional domains include two activation domains (AD1, AD2), a TFIID-interacting domain (AD3), a bHLH motif near the C-terminus, and a nuclear localization sequence (NLS) (chen2021molecularandcellular pages 1-2).

Pathogenic Variants

Variants are classified as pathogenic or likely pathogenic per ACMG/AMP guidelines and include: - Missense variants in the bHLH domain causing loss of DNA-binding and transactivation function - Truncating variants (nonsense, frameshift) causing haploinsufficiency - Large deletions including whole-gene and multi-exon deletions (13% of cases) - Splice-site variants affecting mRNA processing - Recurrent variants such as p.(Arg389Cys) causing atypical phenotypes (popp2022therecurrenttcf4 pages 2-3, popp2022therecurrenttcf4 pages 7-7)

Elongating and missense mutations at the dimer interface of the bHLH domain destabilize the protein, whereas missense mutations outside the bHLH domain cause no apparent functional deficits (chen2021molecularandcellular pages 2-3). Functional consequences range from haploinsufficient expression to dominant-negative or hypomorphic effects (zhao2024clinicalandgenetic pages 9-9, chen2021molecularandcellular pages 1-2).

Epigenetic Information

A DNA methylation episignature for PTHS has been established from 67 genetically confirmed individuals, consisting of predominantly hypermethylated differentially methylated positions (DMPs) mapping within coding regions and CpG island shore regions (laan2024dnamethylationepisignature pages 1-3, laan2024dnamethylationepisignature pages 7-9). An SVM classifier trained on this episignature demonstrates high sensitivity for TCF4 haploinsufficiency and bHLH domain missense variants (laan2024dnamethylationepisignature pages 1-3). The PTHS episignature shows similarity to Coffin-Siris syndrome episignatures, likely reflecting the documented biochemical interaction between TCF4 and SOX11 (laan2024dnamethylationepisignature pages 9-10). However, seven individuals with TCF4 variants exhibited negative episignatures, suggesting complexity related to mosaicism or genetic/environmental influences (laan2024dnamethylationepisignature pages 1-3).

5. Environmental Information

As a monogenic disorder caused by de novo germline mutations, PTHS has no established environmental risk factors, lifestyle factors, or infectious agents contributing to disease causation. Environmental and lifestyle modifications are relevant only in the context of supportive care and symptom management.

6. Mechanism / Pathophysiology

The following table summarizes the major molecular pathways disrupted in PTHS.

Table: This table summarizes major molecular pathways disrupted in Pitt-Hopkins syndrome, linking TCF4 loss to affected genes, cell types, and emerging therapeutic strategies. It is useful for quickly connecting pathophysiology with candidate interventions.

Detailed Pathophysiology

Wnt/β-catenin Pathway Disruption: TCF4 loss-of-function leads to decreased Wnt signaling, diminished SOX target gene expression, and reduced neural progenitor cell proliferation. This results in impaired neuronal differentiation and reduced cortical neuron content in patient-derived organoids, phenotypes that were rescued by pharmacological modulation of Wnt signaling (savchenko2024transcriptionfactortcf4 pages 6-7, chen2021molecularandcellular pages 2-3).

SCN10A/Nav1.8 Ectopic Upregulation: TCF4 normally represses SCN10A expression. Loss of TCF4 function results in ectopic overexpression of Nav1.8 in cortical neurons and brainstem neurons, leading to neuronal hyperexcitability, abnormal network synchronicity, and behavioral deficits (martinowich2023evaluationofnav1.8 pages 1-2, savchenko2024transcriptionfactortcf4 pages 6-7). The Nav1.8 antagonist PF-04531083 significantly reduced gamma event-related spectral perturbation and normalized intertrial coherence at theta and gamma frequencies (martinowich2023evaluationofnav1.8 pages 3-5).

RIMBP2-Mediated Synaptic Dysfunction: TCF4 mutations cause severe downregulation of RIMBP2, a presynaptic binding protein essential for coupling synaptic vesicles, calcium channels, and fusion machinery. This leads to reduced glutamate release, disrupted network activity, and impaired homeostatic plasticity. Restoring RIMBP2 expression rescued spontaneous network activity and normalized presynaptic glutamate release in patient-derived cortical neurons (davis2024tcf4mutationsdisrupt pages 1-3, davis2024tcf4mutationsdisrupt pages 11-12).

Respiratory Control Disruption: In the Tcf4tr/+ mouse model, there is selective loss of Phox2b-expressing parafacial neurons, with 70% fewer Phox2b+ neurons in the parafacial lateral (pFL) region and 21% reduction in the retrotrapezoid nucleus (RTN). These glutamatergic chemoreceptor neurons are critical for CO2/H+ sensing and breathing regulation. Their loss results in periodic breathing, hyperventilation episodes, reduced sigh frequency, prolonged post-sigh apnea, and absent active expiration responses to CO2 challenge (cleary2021disorderedbreathingin pages 2-3, cleary2021disorderedbreathingin pages 1-2, cleary2021disorderedbreathingin pages 3-4, cleary2021disorderedbreathingin pages 4-5). Nav1.8 blockade improved multiple aspects of the respiratory phenotype (cleary2021disorderedbreathingin pages 8-9, cleary2021disorderedbreathingin pages 9-9).

Oligodendrocyte and Myelination Deficits: Transcriptional profiling revealed that differentially expressed genes in PTHS models are enriched in oligodendrocytes, with reduced oligodendrocyte density, myelination, and function. A myelin-related transcriptomic profile is shared between PTHS models and human ASD (martinowich2023evaluationofnav1.8 pages 3-5, kim2022rescueofbehavioral pages 22-23, chen2021molecularandcellular pages 7-8). TCF4 directly targets myelination-related genes including Plp1 and Gjb2 (chen2021molecularandcellular pages 2-3).

MeCP2 Pathway Convergence: MeCP2 levels are decreased in PTHS patient-derived induced neuronal progenitor cells. Genetic crossing of Tcf4+/− mice with MeCP2-overexpressing mice significantly ameliorated molecular and phenotypic defects, and postnatal AAV9-MeCP2 gene therapy improved histological and behavioral deficits (dennys2024mecp2genetherapy pages 1-2).

GO Terms for Key Biological Processes

• GO:0007399 (nervous system development)
• GO:0030182 (neuron differentiation)
• GO:0042552 (myelination)
• GO:0007268 (chemical synaptic transmission)
• GO:0060079 (excitatory postsynaptic potential)
• GO:0007420 (brain development)
• GO:0007585 (respiratory gaseous exchange)

CL Terms for Key Cell Types

• CL:0000540 (neuron)
• CL:0000128 (oligodendrocyte)
• CL:0000127 (astrocyte)
• CL:0000047 (neuronal stem cell)
• CL:0000617 (GABAergic neuron)

7. Anatomical Structures Affected

Organ Level

• Primary: Central nervous system (brain), including cerebral cortex, hippocampus, corpus callosum, cerebellum/vermis, caudate nuclei (chen2021molecularandcellular pages 1-2)
• Secondary: Respiratory system (brainstem respiratory centers), gastrointestinal tract, eyes, skeletal muscle (chiu2024skeletalmusclevulnerability pages 1-2, cleary2021disorderedbreathingin pages 1-2)

Tissue and Cell Level

• Cortical gray matter (neurons, glial cells)
• White matter (oligodendrocytes, myelinated axons)
• Brainstem parafacial region (Phox2b+ chemoreceptor neurons) (cleary2021disorderedbreathingin pages 4-5)
• Retinal tissue (contributing to myopia)
• Skeletal muscle (fiber type I predominance, mitochondrial vulnerability) (chiu2024skeletalmusclevulnerability pages 1-2)

UBERON Terms

• UBERON:0001890 (forebrain)
• UBERON:0002421 (hippocampal formation)
• UBERON:0002336 (corpus callosum)
• UBERON:0001896 (medulla oblongata, containing RTN)
• UBERON:0000955 (brain)

8. Temporal Development

Onset

PTHS typically presents in the first year of life with developmental delay (kim2022rescueofbehavioral pages 1-2). Onset is congenital/infantile. Diagnosis is generally made when infants fail to reach developmental milestones and undergo genetic testing, often at several years of age (james2025juvenilereinstatementof pages 1-5).

Progression

The condition is chronic and lifelong. Core neurodevelopmental features are stable (non-progressive) after the initial developmental period. Motor and speech regression occurs in approximately 6% of patients (zhao2024clinicalandgenetic pages 3-5). Mouse models show synaptic defects but no disease-related neurodegeneration, suggesting that observed defects could be reversible through genetic normalization approaches (kim2022rescueofbehavioral pages 1-2). However, juvenile reinstatement of TCF4 in mice largely fails to correct most phenotypes except cognitive function, revealing phenotype-specific plasticity and underscoring a narrow, early critical window for effective treatment (james2025juvenilereinstatementof pages 1-5).

9. Inheritance and Population

Inheritance Pattern

PTHS is inherited in an autosomal dominant manner, typically caused by de novo genetic alterations. Rare instances of parental mosaicism (germline mosaicism) have been reported (chen2021molecularandcellular pages 1-2). The condition shows complete penetrance for the core intellectual disability phenotype, though expressivity is variable for features such as seizures, breathing abnormalities, and facial features (chen2021molecularandcellular pages 1-2, zhao2024clinicalandgenetic pages 9-9). Boys and girls are affected equally (chiu2024skeletalmusclevulnerability pages 1-2).

Epidemiology

Prevalence estimates vary considerably: - 1 in 225,000 to 300,000 based on UK and Netherlands data (zhao2024clinicalandgenetic pages 1-2) - 1 in 34,000 to 41,000 births based on other estimates (chen2021molecularandcellular pages 1-2)

The discrepancy likely reflects underdiagnosis and ascertainment differences. Reliable figures for prevalence are not fully established (chen2021molecularandcellular pages 1-2). PTHS has been reported across diverse populations including European, Chinese, and other ethnicities, with no confirmed population-specific enrichment (zhao2024clinicalandgenetic pages 1-2, zhao2024clinicalandgenetic pages 7-9).

10. Diagnostics

Clinical Diagnosis

Clinical diagnosis is based on recognition of characteristic features including intellectual disability, facial gestalt, and breathing abnormalities, but accurate diagnosis requires genetic confirmation to rule out overlapping conditions such as Rett syndrome, Angelman syndrome, and Mowat-Wilson syndrome (chen2021molecularandcellular pages 1-2). Consensus diagnostic criteria exist but many features are not fully penetrant, complicating clinical recognition (chen2021molecularandcellular pages 1-2).

Genetic Testing

• Whole exome sequencing (WES): Primary recommended approach; identifies point mutations and small indels (zhao2024clinicalandgenetic pages 3-5)
• Gene panels: Intellectual disability/neurodevelopmental disorder panels including TCF4 (popp2022therecurrenttcf4 pages 2-3)
• Chromosomal microarray (CMA): Detects deletions encompassing the TCF4 locus (~13% of cases) (zhao2024clinicalandgenetic pages 3-5)
• MLPA: Used for confirmation of copy number aberrations (chiu2024skeletalmusclevulnerability pages 1-2)
• Single gene testing: TCF4 sequencing and deletion/duplication analysis

Epigenomic Diagnostics

A DNA methylation episignature for PTHS has been developed using Infinium Methylation EPIC BeadChip array analysis on peripheral blood. An SVM classifier model exhibits high sensitivity for TCF4 loss-of-function variants and enables improved diagnostic accuracy and reclassification of variants of uncertain significance (VUS) (laan2024dnamethylationepisignature pages 1-3, laan2024dnamethylationepisignature pages 4-7). Negative episignature results do not exclude PTHS diagnosis due to factors such as mosaicism or genetic modifiers (laan2024dnamethylationepisignature pages 7-9).

Neuroimaging

Brain MRI reveals abnormalities in 79% of patients, including ventricle enlargement, wide extracranial space, and corpus callosum hypoplasia (zhao2024clinicalandgenetic pages 3-5). Underdevelopment of the corpus callosum, smaller hippocampus, enlarged caudate nuclei, and cerebellar/vermis hypoplasia have been reported (chen2021molecularandcellular pages 1-2).

Differential Diagnosis

Key conditions to differentiate include Rett syndrome (MECP2), Angelman syndrome (UBE3A), Mowat-Wilson syndrome (ZEB2), and Phelan-McDermid syndrome (SHANK3) (chen2021molecularandcellular pages 1-2, dennys2024mecp2genetherapy pages 1-2).

11. Outcome/Prognosis

Survival and Life Expectancy

Limited long-term survival data are available. PTHS is a chronic lifelong condition. There are no established disease-specific mortality data in the literature, though breathing abnormalities and epilepsy may contribute to complications. Adults with PTHS have been described, indicating survival into adulthood (NCT07135050 chunk 1).

Morbidity and Function

PTHS causes significant morbidity with severe intellectual disability, absent or minimal speech, motor impairments, and inability to live independently. Quality of life is substantially impacted, and affected individuals require lifelong care (zhao2024clinicalandgenetic pages 3-5, zhao2024clinicalandgenetic pages 2-3). Adaptive functioning is markedly impaired. Clinical trial outcome measures include QI-Disability, ICND overall quality of life rating, Vineland Adaptive Behavior Scales, and ORCA communication ability measures (NCT05025332 chunk 1, NCT05025332 chunk 2).

Prognostic Factors

No significant correlations between genotype and phenotype severity have been established in large cohorts, though mutations in the bHLH domain and exons 7–8 tend to correlate with more severe intellectual disability (zhao2024clinicalandgenetic pages 7-9, popp2022therecurrenttcf4 pages 2-3). Early intervention and rehabilitation may improve outcomes (zhao2024clinicalandgenetic pages 7-9).

12. Treatment

Current Management (Supportive/Symptomatic)

Currently, treatment of PTHS is entirely focused on managing symptoms, with no therapies targeting the underlying molecular pathology (dennys2024mecp2genetherapy pages 1-2). Supportive measures include: - Rehabilitation: Physical therapy, occupational therapy, speech therapy (MAXO:0000011, MAXO:0000497) - Antiepileptic medications: For seizure management - Ketogenic diet: Shows promising results for refractory epilepsy in PTHS (zhao2024clinicalandgenetic pages 7-9) - Acetazolamide: Used for breathing abnormalities/central apnea (cleary2021disorderedbreathingin pages 13-14) - Behavioral interventions: For ASD-associated behaviors

Clinical Trials

Table: This table summarizes currently identified Pitt-Hopkins syndrome interventional trials, including drug, gene therapy, microbiome, and cell therapy studies. It is useful for quickly comparing intervention types, development stage, recruitment status, and sponsor activity.

Experimental Therapeutics

Gene Therapy Approaches: MZ-1866 (NCT07135050) is an AAV-9 gene therapy delivered by intracerebroventricular injection currently in Phase 1/2 trials (NCT07135050 chunk 1). Preclinical studies demonstrated that postnatally reinstating Tcf4 expression in neurons improved anxiety-like behavior, activity levels, innate behaviors, memory, and partially corrected EEG abnormalities (kim2022rescueofbehavioral pages 1-2). However, juvenile reinstatement largely fails to correct most phenotypes, revealing a narrow early critical window for effective treatment (james2025juvenilereinstatementof pages 1-5).

HDAC Inhibitors: Vorinostat (NCT07150026) is being evaluated based on evidence that pharmacological inhibition of class I histone deacetylases increases TCF4 expression (NCT07150026 chunk 2, chen2021molecularandcellular pages 2-3).

Nav1.8 Antagonists: Preclinical studies show that blocking Nav1.8 with PF-04531083 normalizes neural synchrony, reduces hyperventilation episodes, and improves behavioral phenotypes in PTHS mouse models (martinowich2023evaluationofnav1.8 pages 3-5, cleary2021disorderedbreathingin pages 9-9).

Pro-myelinating Agents: Clemastine fumarate enhances myelination and promotes functional recovery in PTHS mouse models (savchenko2024transcriptionfactortcf4 pages 6-7).

MeCP2-Based Therapy: AAV9-MeCP2 gene therapy significantly improved neuronal progenitor cell and astrocyte function and ameliorated histological and behavioral defects in Tcf4+/− mice (dennys2024mecp2genetherapy pages 1-2).

13. Prevention

Primary Prevention

As PTHS results from de novo mutations, primary prevention is not applicable.

Genetic Counseling

Genetic counseling is recommended for families. Recurrence risk is generally low given the de novo nature, but parental mosaicism should be considered (chen2021molecularandcellular pages 1-2). Prenatal and preimplantation genetic testing is feasible if the family-specific TCF4 variant has been identified.

Screening

There are no population-based newborn screening programs for PTHS. Cascade genetic testing of family members may be indicated when parental mosaicism is suspected. The DNA methylation episignature can serve as a secondary screening/confirmation tool for individuals with suspected PTHS and VUS in TCF4 (laan2024dnamethylationepisignature pages 4-7, laan2024dnamethylationepisignature pages 10-11).

14. Other Species / Natural Disease

PTHS is a human-specific genetic condition caused by de novo TCF4 mutations. No naturally occurring disease analogous to PTHS has been documented in other species. However, TCF4 is evolutionarily conserved, with orthologous genes expressed in mice (Mus musculus, NCBI Taxon 10090), rats, and other vertebrates (chen2021molecularandcellular pages 1-2).

15. Model Organisms

Mouse Models

Multiple mouse models have been developed:

1. Tcf4STOP/+ (conditional model): Contains a loxP-flanked STOP cassette in exon 18, reducing full-length Tcf4 expression by approximately 50%. Recapitulates reduced body/brain weight (microcephaly), long-term memory deficits, increased locomotor activity, and impaired nest-building (kim2022rescueofbehavioral pages 2-4).

2. Tcf4tr/+ (truncation model): Expresses a truncated TCF4 protein. Displays frequent hyperventilation episodes, reduced sigh activity, prolonged post-sigh apnea, blunted ventilatory responses to CO2, and selective loss of parafacial Phox2b+ neurons (cleary2021disorderedbreathingin pages 2-3, cleary2021disorderedbreathingin pages 1-2, cleary2021disorderedbreathingin pages 4-5).

3. Tcf4+/− (heterozygous knockout, Jackson Laboratory stock 013598, B6;129-Tcf4tm1Zhu/J): Used extensively for behavioral, molecular, and gene therapy studies (dennys2024mecp2genetherapy pages 1-2).

Phenotype Recapitulation

Mouse models recapitulate key human PTHS symptoms including intellectual disability (memory deficits), motor delay (locomotor abnormalities), sleep disturbances, microcephaly, breathing disruption, hypotonia, seizures, reduced oligodendrocyte density and myelination, and synaptic dysfunction (james2025juvenilereinstatementof pages 1-5, martinowich2023evaluationofnav1.8 pages 3-5). A myelin-related transcriptomic profile is shared between five PTHS mouse models and human ASD (kim2022rescueofbehavioral pages 22-23).

iPSC-Derived Models

Patient-derived iPSC models include neural progenitor cells, cortical neurons, astrocytes, and brain organoids. These human cellular models demonstrate reduced progenitor proliferation, impaired neuronal differentiation, abnormal organoid size and cellular composition, reduced spontaneous synaptic transmission, and downregulated RIMBP2 expression (savchenko2024transcriptionfactortcf4 pages 6-7, davis2024tcf4mutationsdisrupt pages 1-3, dennys2024mecp2genetherapy pages 1-2).

Research Applications and Limitations

These models have been used for testing therapeutic interventions including HDAC inhibitors, Nav1.8 antagonists, Tcf4 gene reinstatement, MeCP2 gene therapy, and clemastine fumarate (savchenko2024transcriptionfactortcf4 pages 6-7, kim2022rescueofbehavioral pages 1-2). A critical finding from juvenile reinstatement studies is that delayed intervention largely fails to correct most phenotypes except cognitive function, underscoring a narrow early critical window for effective genetic treatment (james2025juvenilereinstatementof pages 1-5).

Summary

Pitt-Hopkins syndrome is a rare monogenic neurodevelopmental disorder caused by haploinsufficiency of TCF4, a bHLH transcription factor critical for brain development. The disease manifests with severe intellectual disability, characteristic facial features, breathing abnormalities, and motor impairments. Molecular studies have revealed that TCF4 regulates multiple downstream pathways including Wnt/β-catenin signaling, SCN10A/Nav1.8 expression, RIMBP2-mediated synaptic function, and oligodendrocyte myelination. A DNA methylation episignature enables improved diagnostic classification. The therapeutic landscape is rapidly evolving, with an AAV-9 gene therapy (NCT07135050), HDAC inhibitor vorinostat (NCT07150026), and NNZ-2591 (NCT05025332, completed) in clinical trials (OpenTargets Search: Pitt-Hopkins syndrome, NCT07135050 chunk 1, NCT07150026 chunk 2, NCT05025332 chunk 1). Preclinical studies support genetic normalization strategies but underscore the importance of early intervention timing (james2025juvenilereinstatementof pages 1-5, kim2022rescueofbehavioral pages 1-2).

References

1. (chen2021molecularandcellular pages 1-2): Huei-Ying Chen, Joseph F. Bohlen, and Brady J. Maher. Molecular and cellular function of transcription factor 4 in pitt-hopkins syndrome. Developmental Neuroscience, 43:159-167, Jun 2021. URL: https://doi.org/10.1159/000516666, doi:10.1159/000516666. This article has 34 citations and is from a peer-reviewed journal.

2. (sweetser2025pitthopkinssyndrome pages 1-1): DA Sweetser, KS Gipson, and C Zar-Kessler. Pitt-hopkins syndrome. Definitions, Feb 2025. URL: https://doi.org/10.4135/9781483392271.n390, doi:10.4135/9781483392271.n390. This article has 58 citations.

3. (martinowich2023evaluationofnav1.8 pages 1-2): Keri Martinowich, Debamitra Das, Srinidhi Rao Sripathy, Yishan Mai, Rakaia F. Kenney, and Brady J. Maher. Evaluation of nav1.8 as a therapeutic target for pitt hopkins syndrome. Molecular Psychiatry, 28:76-82, Oct 2023. URL: https://doi.org/10.1038/s41380-022-01811-4, doi:10.1038/s41380-022-01811-4. This article has 16 citations and is from a highest quality peer-reviewed journal.

4. (zhao2024clinicalandgenetic pages 1-2): Tingting Zhao, Shengnan Wu, Yiping Shen, Jing Leng, Georgi Z. Genchev, Hui Lu, and Jincai Feng. Clinical and genetic characterization of 47 chinese pediatric patients with pitt–hopkins syndrome: a retrospective study. Orphanet Journal of Rare Diseases, Feb 2024. URL: https://doi.org/10.1186/s13023-024-03055-7, doi:10.1186/s13023-024-03055-7. This article has 4 citations and is from a peer-reviewed journal.

5. (jiang2024agenotypicand pages 1-2): Dandan Jiang, Chengqing Yang, Mei Hou, Dianrong Sun, Danni Jiang, and Zongbo Chen. A genotypic and phenotypic analysis of four unrelated chinese patients with pitt–hopkins syndrome. Egyptian Journal of Medical Human Genetics, Oct 2024. URL: https://doi.org/10.1186/s43042-024-00586-3, doi:10.1186/s43042-024-00586-3. This article has 1 citations and is from a peer-reviewed journal.

6. (OpenTargets Search: Pitt-Hopkins syndrome): Open Targets Query (Pitt-Hopkins syndrome, 2 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

7. (chen2021molecularandcellular pages 2-3): Huei-Ying Chen, Joseph F. Bohlen, and Brady J. Maher. Molecular and cellular function of transcription factor 4 in pitt-hopkins syndrome. Developmental Neuroscience, 43:159-167, Jun 2021. URL: https://doi.org/10.1159/000516666, doi:10.1159/000516666. This article has 34 citations and is from a peer-reviewed journal.

8. (popp2022therecurrenttcf4 pages 2-3): Bernt Popp, Thierry Bienvenu, Irina Giurgea, Julia Metreau, Cornelia Kraus, André Reis, Jan Fischer, María Palomares Bralo, Jair Tenorio‐Castaño, Pablo Lapunzina, Berta Almoguera, Fermina Lopez‐Grondona, Heinrich Sticht, and Christiane Zweier. The recurrent tcf4 missense variant p.(arg389cys) causes a neurodevelopmental disorder overlapping with but not typical for pitt‐hopkins syndrome. Clinical Genetics, 102:517-523, Aug 2022. URL: https://doi.org/10.1111/cge.14206, doi:10.1111/cge.14206. This article has 7 citations and is from a peer-reviewed journal.

9. (chiu2024skeletalmusclevulnerability pages 1-2): Celine Chiu, Alma Küchler, Christel Depienne, Corinna Preuße, Adela Della Marina, Andre Reis, Frank J. Kaiser, Kay Nolte, Andreas Hentschel, Ulrike Schara-Schmidt, Heike Kölbel, and Andreas Roos. Skeletal muscle vulnerability in a child with pitt-hopkins syndrome. Skeletal Muscle, Jul 2024. URL: https://doi.org/10.1186/s13395-024-00348-0, doi:10.1186/s13395-024-00348-0. This article has 1 citations and is from a peer-reviewed journal.

10. (zhao2024clinicalandgenetic pages 3-5): Tingting Zhao, Shengnan Wu, Yiping Shen, Jing Leng, Georgi Z. Genchev, Hui Lu, and Jincai Feng. Clinical and genetic characterization of 47 chinese pediatric patients with pitt–hopkins syndrome: a retrospective study. Orphanet Journal of Rare Diseases, Feb 2024. URL: https://doi.org/10.1186/s13023-024-03055-7, doi:10.1186/s13023-024-03055-7. This article has 4 citations and is from a peer-reviewed journal.

11. (zhao2024clinicalandgenetic pages 7-9): Tingting Zhao, Shengnan Wu, Yiping Shen, Jing Leng, Georgi Z. Genchev, Hui Lu, and Jincai Feng. Clinical and genetic characterization of 47 chinese pediatric patients with pitt–hopkins syndrome: a retrospective study. Orphanet Journal of Rare Diseases, Feb 2024. URL: https://doi.org/10.1186/s13023-024-03055-7, doi:10.1186/s13023-024-03055-7. This article has 4 citations and is from a peer-reviewed journal.

12. (zhao2024clinicalandgenetic pages 2-3): Tingting Zhao, Shengnan Wu, Yiping Shen, Jing Leng, Georgi Z. Genchev, Hui Lu, and Jincai Feng. Clinical and genetic characterization of 47 chinese pediatric patients with pitt–hopkins syndrome: a retrospective study. Orphanet Journal of Rare Diseases, Feb 2024. URL: https://doi.org/10.1186/s13023-024-03055-7, doi:10.1186/s13023-024-03055-7. This article has 4 citations and is from a peer-reviewed journal.

13. (cleary2021disorderedbreathingin pages 2-3): C. M. Cleary, S. James, B. J. Maher, and D. K. Mulkey. Disordered breathing in a pitt-hopkins syndrome model involves phox2b-expressing parafacial neurons and aberrant nav1.8 expression. Nature Communications, Oct 2021. URL: https://doi.org/10.1038/s41467-021-26263-2, doi:10.1038/s41467-021-26263-2. This article has 22 citations and is from a highest quality peer-reviewed journal.

14. (cleary2021disorderedbreathingin pages 1-2): C. M. Cleary, S. James, B. J. Maher, and D. K. Mulkey. Disordered breathing in a pitt-hopkins syndrome model involves phox2b-expressing parafacial neurons and aberrant nav1.8 expression. Nature Communications, Oct 2021. URL: https://doi.org/10.1038/s41467-021-26263-2, doi:10.1038/s41467-021-26263-2. This article has 22 citations and is from a highest quality peer-reviewed journal.

15. (cleary2021disorderedbreathingin pages 9-9): C. M. Cleary, S. James, B. J. Maher, and D. K. Mulkey. Disordered breathing in a pitt-hopkins syndrome model involves phox2b-expressing parafacial neurons and aberrant nav1.8 expression. Nature Communications, Oct 2021. URL: https://doi.org/10.1038/s41467-021-26263-2, doi:10.1038/s41467-021-26263-2. This article has 22 citations and is from a highest quality peer-reviewed journal.

16. (dennys2024mecp2genetherapy pages 1-2): Cassandra N. Dennys, Sheryl Anne D. Vermudez, Robert J.M. Deacon, J. Andrea Sierra-Delgado, Kelly Rich, Xiaojin Zhang, Aditi Buch, Kelly Weiss, Yuta Moxley, Hemangi Rajpal, Francisca D. Espinoza, Samantha Powers, Ariel S. Ávila, Rocco G. Gogliotti, Patricia Cogram, Colleen M. Niswender, and Kathrin C. Meyer. Mecp2 gene therapy ameliorates disease phenotype in mouse model for pitt hopkins syndrome. Neurotherapeutics, 21:e00376, Sep 2024. URL: https://doi.org/10.1016/j.neurot.2024.e00376, doi:10.1016/j.neurot.2024.e00376. This article has 7 citations and is from a peer-reviewed journal.

17. (james2025juvenilereinstatementof pages 1-5): Lucas M. James, Carlee A. Friar, Siyuan Liang, Eric B. Gao, Alain. C. Burette, and Benjamin D. Philpot. Juvenile reinstatement of tcf4 in pitt-hopkins syndrome model mice reveals a critical window for genetic intervention. bioRxiv, Dec 2025. URL: https://doi.org/10.64898/2025.12.23.696277, doi:10.64898/2025.12.23.696277. This article has 0 citations.

18. (popp2022therecurrenttcf4 pages 7-7): Bernt Popp, Thierry Bienvenu, Irina Giurgea, Julia Metreau, Cornelia Kraus, André Reis, Jan Fischer, María Palomares Bralo, Jair Tenorio‐Castaño, Pablo Lapunzina, Berta Almoguera, Fermina Lopez‐Grondona, Heinrich Sticht, and Christiane Zweier. The recurrent tcf4 missense variant p.(arg389cys) causes a neurodevelopmental disorder overlapping with but not typical for pitt‐hopkins syndrome. Clinical Genetics, 102:517-523, Aug 2022. URL: https://doi.org/10.1111/cge.14206, doi:10.1111/cge.14206. This article has 7 citations and is from a peer-reviewed journal.

19. (zhao2024clinicalandgenetic pages 9-9): Tingting Zhao, Shengnan Wu, Yiping Shen, Jing Leng, Georgi Z. Genchev, Hui Lu, and Jincai Feng. Clinical and genetic characterization of 47 chinese pediatric patients with pitt–hopkins syndrome: a retrospective study. Orphanet Journal of Rare Diseases, Feb 2024. URL: https://doi.org/10.1186/s13023-024-03055-7, doi:10.1186/s13023-024-03055-7. This article has 4 citations and is from a peer-reviewed journal.

20. (laan2024dnamethylationepisignature pages 1-3): Liselot van der Laan, Peter Lauffer, Kathleen Rooney, Ananília Silva, Sadegheh Haghshenas, Raissa Relator, Michael A. Levy, Slavica Trajkova, Sylvia A. Huisman, Emilia K. Bijlsma, Tjitske Kleefstra, Bregje W. van Bon, Özlem Baysal, Christiane Zweier, María Palomares-Bralo, Jan Fischer, Katalin Szakszon, Laurence Faivre, Amélie Piton, Simone Mesman, Ron Hochstenbach, Mariet W. Elting, Johanna M. van Hagen, Astrid S. Plomp, Marcel M.A.M. Mannens, Mariëlle Alders, Mieke M. van Haelst, Giovanni B. Ferrero, Alfredo Brusco, Peter Henneman, David A. Sweetser, Bekim Sadikovic, Antonio Vitobello, and Leonie A. Menke. Dna methylation episignature and comparative epigenomic profiling for pitt-hopkins syndrome caused by tcf4 variants. Human Genetics and Genomics Advances, 5:100289, Jul 2024. URL: https://doi.org/10.1016/j.xhgg.2024.100289, doi:10.1016/j.xhgg.2024.100289. This article has 7 citations and is from a peer-reviewed journal.

21. (laan2024dnamethylationepisignature pages 7-9): Liselot van der Laan, Peter Lauffer, Kathleen Rooney, Ananília Silva, Sadegheh Haghshenas, Raissa Relator, Michael A. Levy, Slavica Trajkova, Sylvia A. Huisman, Emilia K. Bijlsma, Tjitske Kleefstra, Bregje W. van Bon, Özlem Baysal, Christiane Zweier, María Palomares-Bralo, Jan Fischer, Katalin Szakszon, Laurence Faivre, Amélie Piton, Simone Mesman, Ron Hochstenbach, Mariet W. Elting, Johanna M. van Hagen, Astrid S. Plomp, Marcel M.A.M. Mannens, Mariëlle Alders, Mieke M. van Haelst, Giovanni B. Ferrero, Alfredo Brusco, Peter Henneman, David A. Sweetser, Bekim Sadikovic, Antonio Vitobello, and Leonie A. Menke. Dna methylation episignature and comparative epigenomic profiling for pitt-hopkins syndrome caused by tcf4 variants. Human Genetics and Genomics Advances, 5:100289, Jul 2024. URL: https://doi.org/10.1016/j.xhgg.2024.100289, doi:10.1016/j.xhgg.2024.100289. This article has 7 citations and is from a peer-reviewed journal.

22. (laan2024dnamethylationepisignature pages 9-10): Liselot van der Laan, Peter Lauffer, Kathleen Rooney, Ananília Silva, Sadegheh Haghshenas, Raissa Relator, Michael A. Levy, Slavica Trajkova, Sylvia A. Huisman, Emilia K. Bijlsma, Tjitske Kleefstra, Bregje W. van Bon, Özlem Baysal, Christiane Zweier, María Palomares-Bralo, Jan Fischer, Katalin Szakszon, Laurence Faivre, Amélie Piton, Simone Mesman, Ron Hochstenbach, Mariet W. Elting, Johanna M. van Hagen, Astrid S. Plomp, Marcel M.A.M. Mannens, Mariëlle Alders, Mieke M. van Haelst, Giovanni B. Ferrero, Alfredo Brusco, Peter Henneman, David A. Sweetser, Bekim Sadikovic, Antonio Vitobello, and Leonie A. Menke. Dna methylation episignature and comparative epigenomic profiling for pitt-hopkins syndrome caused by tcf4 variants. Human Genetics and Genomics Advances, 5:100289, Jul 2024. URL: https://doi.org/10.1016/j.xhgg.2024.100289, doi:10.1016/j.xhgg.2024.100289. This article has 7 citations and is from a peer-reviewed journal.

23. (savchenko2024transcriptionfactortcf4 pages 6-7): R. R. Savchenko and N. A. Skryabin. Transcription factor tcf4: structure, function, and associated diseases. Vavilov Journal of Genetics and Breeding, 28:770-779, Nov 2024. URL: https://doi.org/10.18699/vjgb-24-85, doi:10.18699/vjgb-24-85. This article has 5 citations.

24. (martinowich2023evaluationofnav1.8 pages 3-5): Keri Martinowich, Debamitra Das, Srinidhi Rao Sripathy, Yishan Mai, Rakaia F. Kenney, and Brady J. Maher. Evaluation of nav1.8 as a therapeutic target for pitt hopkins syndrome. Molecular Psychiatry, 28:76-82, Oct 2023. URL: https://doi.org/10.1038/s41380-022-01811-4, doi:10.1038/s41380-022-01811-4. This article has 16 citations and is from a highest quality peer-reviewed journal.

25. (davis2024tcf4mutationsdisrupt pages 1-3): Brittany A. Davis, Huei-Ying Chen, Zengyou Ye, Isaac Ostlund, Madhavi Tippani, Debamitra Das, Srinidhi Rao Sripathy, Yanhong Wang, Jacqueline M. Martin, Gina Shim, Neel M. Panchwagh, Rebecca L. Moses, Federica Farinelli, Joseph F. Bohlen, Meijie Li, Bryan W. Luikart, Andrew E. Jaffe, and Brady J. Maher. Tcf4 mutations disrupt synaptic function through dysregulation of rimbp2 in patient-derived cortical neurons. Biological Psychiatry, 95:662-675, Apr 2024. URL: https://doi.org/10.1016/j.biopsych.2023.07.021, doi:10.1016/j.biopsych.2023.07.021. This article has 19 citations and is from a highest quality peer-reviewed journal.

26. (davis2024tcf4mutationsdisrupt pages 11-12): Brittany A. Davis, Huei-Ying Chen, Zengyou Ye, Isaac Ostlund, Madhavi Tippani, Debamitra Das, Srinidhi Rao Sripathy, Yanhong Wang, Jacqueline M. Martin, Gina Shim, Neel M. Panchwagh, Rebecca L. Moses, Federica Farinelli, Joseph F. Bohlen, Meijie Li, Bryan W. Luikart, Andrew E. Jaffe, and Brady J. Maher. Tcf4 mutations disrupt synaptic function through dysregulation of rimbp2 in patient-derived cortical neurons. Biological Psychiatry, 95:662-675, Apr 2024. URL: https://doi.org/10.1016/j.biopsych.2023.07.021, doi:10.1016/j.biopsych.2023.07.021. This article has 19 citations and is from a highest quality peer-reviewed journal.

27. (savchenko2024transcriptionfactortcf4 pages 8-9): R. R. Savchenko and N. A. Skryabin. Transcription factor tcf4: structure, function, and associated diseases. Vavilov Journal of Genetics and Breeding, 28:770-779, Nov 2024. URL: https://doi.org/10.18699/vjgb-24-85, doi:10.18699/vjgb-24-85. This article has 5 citations.

28. (chen2021molecularandcellular pages 3-4): Huei-Ying Chen, Joseph F. Bohlen, and Brady J. Maher. Molecular and cellular function of transcription factor 4 in pitt-hopkins syndrome. Developmental Neuroscience, 43:159-167, Jun 2021. URL: https://doi.org/10.1159/000516666, doi:10.1159/000516666. This article has 34 citations and is from a peer-reviewed journal.

29. (hyojin2021preclinicaldevelopmentof pages 139-143): Preclinical Development of Genetic Normalization Strategies to Treat Pitt-Hopkins Syndrome This article has 0 citations and is from a peer-reviewed journal.

30. (kim2022rescueofbehavioral pages 22-23): Hyojin Kim, Eric B. Gao, Adam Draper, Noah C. Berens, Hanna Vihma, Xinyuan Zhang, Alexandra Higashi-Howard, Kimberly D. Ritola, Jeremy M. Simon, Andrew J. Kennedy, and Benjamin D. Philpot. Rescue of behavioral and electrophysiological phenotypes in a pitt-hopkins syndrome mouse model by genetic restoration of tcf4 expression. eLife, Aug 2022. URL: https://doi.org/10.7554/elife.72290, doi:10.7554/elife.72290. This article has 29 citations and is from a domain leading peer-reviewed journal.

31. (cleary2021disorderedbreathingin pages 3-4): C. M. Cleary, S. James, B. J. Maher, and D. K. Mulkey. Disordered breathing in a pitt-hopkins syndrome model involves phox2b-expressing parafacial neurons and aberrant nav1.8 expression. Nature Communications, Oct 2021. URL: https://doi.org/10.1038/s41467-021-26263-2, doi:10.1038/s41467-021-26263-2. This article has 22 citations and is from a highest quality peer-reviewed journal.

32. (cleary2021disorderedbreathingin pages 13-14): C. M. Cleary, S. James, B. J. Maher, and D. K. Mulkey. Disordered breathing in a pitt-hopkins syndrome model involves phox2b-expressing parafacial neurons and aberrant nav1.8 expression. Nature Communications, Oct 2021. URL: https://doi.org/10.1038/s41467-021-26263-2, doi:10.1038/s41467-021-26263-2. This article has 22 citations and is from a highest quality peer-reviewed journal.

33. (laan2024dnamethylationepisignature pages 4-7): Liselot van der Laan, Peter Lauffer, Kathleen Rooney, Ananília Silva, Sadegheh Haghshenas, Raissa Relator, Michael A. Levy, Slavica Trajkova, Sylvia A. Huisman, Emilia K. Bijlsma, Tjitske Kleefstra, Bregje W. van Bon, Özlem Baysal, Christiane Zweier, María Palomares-Bralo, Jan Fischer, Katalin Szakszon, Laurence Faivre, Amélie Piton, Simone Mesman, Ron Hochstenbach, Mariet W. Elting, Johanna M. van Hagen, Astrid S. Plomp, Marcel M.A.M. Mannens, Mariëlle Alders, Mieke M. van Haelst, Giovanni B. Ferrero, Alfredo Brusco, Peter Henneman, David A. Sweetser, Bekim Sadikovic, Antonio Vitobello, and Leonie A. Menke. Dna methylation episignature and comparative epigenomic profiling for pitt-hopkins syndrome caused by tcf4 variants. Human Genetics and Genomics Advances, 5:100289, Jul 2024. URL: https://doi.org/10.1016/j.xhgg.2024.100289, doi:10.1016/j.xhgg.2024.100289. This article has 7 citations and is from a peer-reviewed journal.

34. (NCT07150026 chunk 2): An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome. Unravel Biosciences, Inc.. 2026. ClinicalTrials.gov Identifier: NCT07150026

35. (cleary2021disorderedbreathingin pages 4-5): C. M. Cleary, S. James, B. J. Maher, and D. K. Mulkey. Disordered breathing in a pitt-hopkins syndrome model involves phox2b-expressing parafacial neurons and aberrant nav1.8 expression. Nature Communications, Oct 2021. URL: https://doi.org/10.1038/s41467-021-26263-2, doi:10.1038/s41467-021-26263-2. This article has 22 citations and is from a highest quality peer-reviewed journal.

36. (cleary2021disorderedbreathingin pages 8-9): C. M. Cleary, S. James, B. J. Maher, and D. K. Mulkey. Disordered breathing in a pitt-hopkins syndrome model involves phox2b-expressing parafacial neurons and aberrant nav1.8 expression. Nature Communications, Oct 2021. URL: https://doi.org/10.1038/s41467-021-26263-2, doi:10.1038/s41467-021-26263-2. This article has 22 citations and is from a highest quality peer-reviewed journal.

37. (chen2021molecularandcellular pages 7-8): Huei-Ying Chen, Joseph F. Bohlen, and Brady J. Maher. Molecular and cellular function of transcription factor 4 in pitt-hopkins syndrome. Developmental Neuroscience, 43:159-167, Jun 2021. URL: https://doi.org/10.1159/000516666, doi:10.1159/000516666. This article has 34 citations and is from a peer-reviewed journal.

38. (kim2022rescueofbehavioral pages 1-2): Hyojin Kim, Eric B. Gao, Adam Draper, Noah C. Berens, Hanna Vihma, Xinyuan Zhang, Alexandra Higashi-Howard, Kimberly D. Ritola, Jeremy M. Simon, Andrew J. Kennedy, and Benjamin D. Philpot. Rescue of behavioral and electrophysiological phenotypes in a pitt-hopkins syndrome mouse model by genetic restoration of tcf4 expression. eLife, Aug 2022. URL: https://doi.org/10.7554/elife.72290, doi:10.7554/elife.72290. This article has 29 citations and is from a domain leading peer-reviewed journal.

39. (NCT07135050 chunk 1): Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome. Mahzi Therapeutics. 2025. ClinicalTrials.gov Identifier: NCT07135050

40. (NCT05025332 chunk 1): An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001). Neuren Pharmaceuticals Limited. 2022. ClinicalTrials.gov Identifier: NCT05025332

41. (NCT05025332 chunk 2): An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001). Neuren Pharmaceuticals Limited. 2022. ClinicalTrials.gov Identifier: NCT05025332

42. (NCT04132427 chunk 1): MTT for Children With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders. Arizona State University. 2019. ClinicalTrials.gov Identifier: NCT04132427

43. (NCT05165017 chunk 1): Safety & Efficacy of AlloRx SC® in PTHS Patients. Vitro Biopharma Inc.. 2021. ClinicalTrials.gov Identifier: NCT05165017

44. (laan2024dnamethylationepisignature pages 10-11): Liselot van der Laan, Peter Lauffer, Kathleen Rooney, Ananília Silva, Sadegheh Haghshenas, Raissa Relator, Michael A. Levy, Slavica Trajkova, Sylvia A. Huisman, Emilia K. Bijlsma, Tjitske Kleefstra, Bregje W. van Bon, Özlem Baysal, Christiane Zweier, María Palomares-Bralo, Jan Fischer, Katalin Szakszon, Laurence Faivre, Amélie Piton, Simone Mesman, Ron Hochstenbach, Mariet W. Elting, Johanna M. van Hagen, Astrid S. Plomp, Marcel M.A.M. Mannens, Mariëlle Alders, Mieke M. van Haelst, Giovanni B. Ferrero, Alfredo Brusco, Peter Henneman, David A. Sweetser, Bekim Sadikovic, Antonio Vitobello, and Leonie A. Menke. Dna methylation episignature and comparative epigenomic profiling for pitt-hopkins syndrome caused by tcf4 variants. Human Genetics and Genomics Advances, 5:100289, Jul 2024. URL: https://doi.org/10.1016/j.xhgg.2024.100289, doi:10.1016/j.xhgg.2024.100289. This article has 7 citations and is from a peer-reviewed journal.

45. (kim2022rescueofbehavioral pages 2-4): Hyojin Kim, Eric B. Gao, Adam Draper, Noah C. Berens, Hanna Vihma, Xinyuan Zhang, Alexandra Higashi-Howard, Kimberly D. Ritola, Jeremy M. Simon, Andrew J. Kennedy, and Benjamin D. Philpot. Rescue of behavioral and electrophysiological phenotypes in a pitt-hopkins syndrome mouse model by genetic restoration of tcf4 expression. eLife, Aug 2022. URL: https://doi.org/10.7554/elife.72290, doi:10.7554/elife.72290. This article has 29 citations and is from a domain leading peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01
• Edison artifact artifact-02
• Edison artifact artifact-03